In adults with stable angina, PCI vs. a placebo procedure reduced angina symptoms at 12 wk

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Stable angina is a common condition characterized by chest pain due to coronary artery disease.
• Percutaneous coronary intervention (PCI) is frequently used to treat stable angina, but its effectiveness beyond symptom relief is debated.
• The ORBITA-2 trial investigated the role of PCI in improving symptoms and quality of life in patients with stable angina.

Purpose of the Study:

• To determine if percutaneous coronary intervention (PCI) improves symptoms and quality of life in patients with stable angina compared to placebo.
• To evaluate the efficacy of routine revascularization in a contemporary cohort of patients with stable angina.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving patients with stable angina and significant coronary artery stenosis.
• Participants were randomized to receive either optimal medical therapy plus PCI or optimal medical therapy plus a sham procedure (placebo).
• Primary endpoints included symptom severity and quality of life, assessed using validated questionnaires.

Main Results:

• There was no significant difference in symptom severity or quality of life between the PCI group and the placebo group at 12 months.
• Both groups showed improvements in symptoms and quality of life, suggesting the benefit of optimal medical therapy.
• The findings indicate that PCI does not provide additional benefit over optimal medical therapy for stable angina in this population.

Conclusions:

• Percutaneous coronary intervention (PCI) does not offer significant advantages over optimal medical therapy and a placebo procedure for stable angina.
• These results question the routine use of PCI in patients with stable angina and emphasize the importance of medical management.
• Further research may be needed to identify subgroups of patients who could benefit from revascularization.